Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP

22NW LP reduced its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 36.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 358,325 shares of the company’s stock after selling 201,717 shares during the quarter. Mineralys Therapeutics accounts for approximately 7.1% of 22NW LP’s holdings, making the stock its 5th largest holding. 22NW LP owned about 0.45% of Mineralys Therapeutics worth $13,588,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MLYS. Smartleaf Asset Management LLC raised its stake in shares of Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Mineralys Therapeutics by 42.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after purchasing an additional 1,197 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Mineralys Therapeutics by 14,091.3% in the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after purchasing an additional 3,241 shares during the period. Police & Firemen s Retirement System of New Jersey grew its holdings in Mineralys Therapeutics by 29.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,234 shares of the company’s stock valued at $125,000 after purchasing an additional 2,098 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in Mineralys Therapeutics during the 2nd quarter valued at $141,000. 84.46% of the stock is owned by institutional investors and hedge funds.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: NDA accepted by FDA and PDUFA set (Dec. 22, 2026) for lorundrostat — formal regulatory review underway, which de-risks timing for potential approval and commercialization. GlobeNewswire: Q4 results & NDA acceptance
• Positive Sentiment: Q4 results surprised to the upside — reported EPS of ($0.40) vs. consensus ($0.57), suggesting operational execution beat expectations and reducing near-term downside to estimates. MarketBeat: Q4 earnings summary
• Positive Sentiment: Management is actively preparing for launch and payer engagement ahead of the regulatory decision — signaling commercialization planning and market-access work that could speed uptake if approved. Seeking Alpha: Launch & payer engagement
• Neutral Sentiment: Conference call and transcript provide management’s roadmap and data context (Q4 call reviewed NDA strategy, clinical data and next steps); useful for modeling but not a surprise item. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Press coverage highlights steady progress with FDA interactions and public messaging; these articles reiterate facts rather than deliver new catalysts. Yahoo Finance: FDA progress TipRanks: NDA acceptance overview
• Negative Sentiment: Critical commentary warns of potential interference from larger pharma interests that could complicate the approval or market dynamics — introduces regulatory and competitive risk that can pressure shares. Seeking Alpha: Concerns over big pharma pressure

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Stifel Nicolaus raised their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Bank of America lifted their target price on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright set a $56.00 price target on Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $49.14.

Mineralys Therapeutics Trading Down 3.0%

Shares of NASDAQ MLYS opened at $26.19 on Friday. Mineralys Therapeutics, Inc. has a 12-month low of $10.44 and a 12-month high of $47.65. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -11.05 and a beta of 0.57. The stock’s 50 day simple moving average is $30.45 and its 200 day simple moving average is $35.51.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. As a group, equities analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Jon Congleton sold 16,236 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.62, for a total value of $529,618.32. Following the sale, the chief executive officer directly owned 639,151 shares in the company, valued at $20,849,105.62. This trade represents a 2.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Malcom Rodman sold 192,715 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30. Following the transaction, the insider directly owned 61,804 shares of the company’s stock, valued at $2,164,376.08. The trade was a 75.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 342,919 shares of company stock valued at $11,755,439. 25.56% of the stock is currently owned by company insiders.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.